[go: up one dir, main page]

BR9914858A - Inibidores de biosìntese sintase h de endoperóxido de prostaglandina - Google Patents

Inibidores de biosìntese sintase h de endoperóxido de prostaglandina

Info

Publication number
BR9914858A
BR9914858A BR9914858-7A BR9914858A BR9914858A BR 9914858 A BR9914858 A BR 9914858A BR 9914858 A BR9914858 A BR 9914858A BR 9914858 A BR9914858 A BR 9914858A
Authority
BR
Brazil
Prior art keywords
cox
inhibitors
cyclooxygenase
kidneys
biosynthesis inhibitors
Prior art date
Application number
BR9914858-7A
Other languages
English (en)
Inventor
Lawrence A Black
Anwer Basha
Teodozyj Kolasa
Michael E Kort
Huaqing Liu
Catherine M Mccarty
Meena V Patel
Jeffrey J Rohde
Michael J Coghlan
Andrew O Stewart
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Priority claimed from US09/427,768 external-priority patent/US6307047B1/en
Publication of BR9914858A publication Critical patent/BR9914858A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"INIBIDORES DE BIOSìNTESE SINTASE H DE ENDOPERóXIDO DE PROSTAGLANDINA". A presente invenção descreve compostos de piridazinona da fórmula (I) que são inibidores de ciclooxigenase (COX) e especificamente, são inibidores seletivos de ciclooxigenase-2 (COX-2), COX-2 é a isoforma induzível associada à inflamação, quando oposta à isoforma constitutiva, ciclooxigenase-1 (COX-1) que é uma enzima "organizadora", em muitos tecidos, incluindo o trato gastrointestinal (GI) e os rins. A seletividade destes compostos para COX-2 minimiza os efeitos colaterais em GI e renais indesejados, vistos nos medicamentos anti-inflamatórios não esteróides comercializados correntemente.
BR9914858-7A 1998-10-27 1999-10-27 Inibidores de biosìntese sintase h de endoperóxido de prostaglandina BR9914858A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17960598A 1998-10-27 1998-10-27
US26187299A 1999-03-03 1999-03-03
US29849099A 1999-04-23 1999-04-23
US09/427,768 US6307047B1 (en) 1997-08-22 1999-10-27 Prostaglandin endoperoxide H synthase biosynthesis inhibitors
PCT/US1999/025234 WO2000024719A1 (en) 1998-10-27 1999-10-27 Prostaglandin endoperoxide h synthase biosynthesis inhibitors

Publications (1)

Publication Number Publication Date
BR9914858A true BR9914858A (pt) 2002-02-05

Family

ID=27497355

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914858-7A BR9914858A (pt) 1998-10-27 1999-10-27 Inibidores de biosìntese sintase h de endoperóxido de prostaglandina

Country Status (19)

Country Link
EP (1) EP1124804B1 (pt)
JP (1) JP2003512292A (pt)
KR (1) KR100666838B1 (pt)
CN (1) CN1279026C (pt)
AT (1) ATE302759T1 (pt)
BG (1) BG65261B1 (pt)
BR (1) BR9914858A (pt)
CA (1) CA2347982A1 (pt)
CZ (1) CZ300570B6 (pt)
DE (1) DE69926903T2 (pt)
DK (1) DK1124804T3 (pt)
ES (1) ES2249919T3 (pt)
HK (1) HK1041876B (pt)
HU (1) HUP0105248A3 (pt)
NO (1) NO318623B1 (pt)
PL (1) PL198503B1 (pt)
SK (1) SK286806B6 (pt)
TR (1) TR200101765T2 (pt)
WO (1) WO2000024719A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU738595B2 (en) 1997-11-19 2001-09-20 Kowa Co., Ltd. Novel pyridazine derivatives and medicines containing the same as effective ingredients
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
JP2000247959A (ja) 1999-02-26 2000-09-12 Kowa Co ピリダジン−３−オン誘導体及びこれを含有する医薬
US7172769B2 (en) 1999-12-08 2007-02-06 Pharmacia Corporation Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
US6664256B1 (en) 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
AR030741A1 (es) 2000-09-15 2003-09-03 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-5-heptenoico y - heptinoico utiles como inhibidores de oxido nitrico sintetasa
AR031129A1 (es) 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
US7012098B2 (en) 2001-03-23 2006-03-14 Pharmacia Corporation Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
DE10129320A1 (de) 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
JP4164031B2 (ja) 2002-02-14 2008-10-08 ファルマシア コーポレーション Ｐ３８ｍａｐキナーゼのモジュレータとしての置換されたピリジノン
PT1572173E (pt) 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
CA2518227A1 (en) 2003-03-18 2004-09-30 Kowa Co., Ltd Water-soluble phenylpyridazine derivative and medicine containing the same
WO2004098619A2 (en) 2003-05-07 2004-11-18 Osteologix A/S Treating cartilage / bone conditions with water-soluble strontium salts
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
EP1916240A1 (en) * 2006-10-25 2008-04-30 Syngeta Participations AG Pyridazine derivatives
ES2367881T3 (es) 2006-12-22 2011-11-10 Recordati Ireland Limited Politerapia para trastornos de las vías urinarias inferiores con ligandos a2d y los aine.
DE102007008839A1 (de) * 2007-02-23 2008-08-28 Bayer Healthcare Ag Verfahren zur Herstellung von 4-(3-Hydroxy-3-methyl-butoxy)-5-[4-(methylsulfonyl)phenyl]-2-arylpyridazin-3(2H)-onen
DE102007008843A1 (de) 2007-02-23 2008-08-28 Bayer Healthcare Ag Verfahren zur Herstellung von 4,5-Dihalogen-2-aryl-2H-pyridazin-3-onen
DE102007008840A1 (de) 2007-02-23 2008-08-28 Bayer Healthcare Ag Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy)-5-[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP)
DE102007020689A1 (de) 2007-05-03 2008-11-06 Bayer Healthcare Ag Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy-5-[4-methylsulfonyl)phenyl]3/2H)-pyridazinon (FHMP)
DE102007020690A1 (de) * 2007-05-03 2008-11-06 Bayer Healthcare Ag Neue amorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-mehtyl-1-butoxy)-6[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP)
DE102007025717A1 (de) * 2007-06-01 2008-12-11 Merck Patent Gmbh Arylether-pyridazinonderivate
GB0716414D0 (en) * 2007-08-22 2007-10-03 Syngenta Participations Ag Novel insecticides
WO2009036132A1 (en) 2007-09-11 2009-03-19 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole n-oxides
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
JP2012131708A (ja) * 2009-04-28 2012-07-12 Nissan Chem Ind Ltd ４位置換ピリダジノン化合物及びｐ２ｘ７受容体阻害剤
FR2969606B1 (fr) * 2010-12-22 2013-01-11 Pf Medicament Derives de diarylpyridazinones, leur preparation et leur application en therapeutique humaine
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
WO2018049015A1 (en) 2016-09-07 2018-03-15 Trustees Of Tufts College Combination therapies using immuno-dash inhibitors and pd-1 antagonists
CN107334767B (zh) * 2017-06-08 2019-03-05 中国医学科学院医药生物技术研究所 一种哒嗪酮类化合物在肿瘤治疗中的应用
WO2021124344A1 (en) * 2019-12-18 2021-06-24 Abida Pyridazine derivatives and their use as cyclooxygenase-2 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4238490A (en) * 1979-02-12 1980-12-09 Diamond Shamrock Corporation Antihypertensive pyridazin(2H)-3-ones
JPS57501328A (pt) * 1980-08-07 1982-07-29
US5622948A (en) * 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
EP0833664A1 (en) * 1995-06-12 1998-04-08 G.D. SEARLE & CO. Combination of a cyclooxygenase-2 inhibitor and a leukotriene b 4? receptor antagonist for the treatment of inflammations
CA2283399C (en) * 1997-03-14 2006-02-21 Merck Frosst Canada & Co. Pyridazinones as inhibitors of cyclooxygenase-2
CA2299300C (en) * 1997-08-22 2007-04-17 Abbott Laboratories Arylpyridazinones as prostaglandin endoperoxide h synthase bisoynthesis inhibitors
WO1999010332A1 (en) * 1997-08-22 1999-03-04 Abbott Laboratories Prostaglandin endoperoxide h synthase biosynthesis inhibitors
HUP0400909A3 (en) * 1997-08-22 2004-10-28 Abbott Lab Arylpyridazinone-derivatives having prostaglandin endoperoxide h synthase biosynthesis inhibitor effect and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
ATE302759T1 (de) 2005-09-15
JP2003512292A (ja) 2003-04-02
KR100666838B1 (ko) 2007-01-11
KR20010081101A (ko) 2001-08-27
BG65261B1 (bg) 2007-10-31
EP1124804B1 (en) 2005-08-24
CZ20011481A3 (cs) 2001-09-12
HK1041876B (en) 2006-06-23
SK286806B6 (sk) 2009-05-07
NO20012061D0 (no) 2001-04-26
WO2000024719A1 (en) 2000-05-04
CA2347982A1 (en) 2000-05-04
PL198503B1 (pl) 2008-06-30
EP1124804A1 (en) 2001-08-22
DE69926903D1 (en) 2005-09-29
CN1342149A (zh) 2002-03-27
DE69926903T2 (de) 2006-07-13
HUP0105248A3 (en) 2002-09-30
CZ300570B6 (cs) 2009-06-17
ES2249919T3 (es) 2006-04-01
NO20012061L (no) 2001-06-27
DK1124804T3 (da) 2005-12-12
BG105523A (en) 2001-12-29
SK5542001A3 (en) 2001-12-03
HK1041876A1 (en) 2002-07-26
CN1279026C (zh) 2006-10-11
HUP0105248A2 (hu) 2002-07-29
TR200101765T2 (tr) 2002-02-21
PL349256A1 (en) 2002-07-01
NO318623B1 (no) 2005-04-18

Similar Documents

Publication Publication Date Title
BR9914858A (pt) Inibidores de biosìntese sintase h de endoperóxido de prostaglandina
BR9812127A (pt) Arilpiridazinonas como inibidores da biossìntese de prostagleina endoperóxido h sintase
ATE319691T1 (de) Prostaglandin endoperoxyde h synthase biosynthese inhibitoren
Chan et al. Hydrogen sulfide-based therapeutics and gastrointestinal diseases: translating physiology to treatments
Esser et al. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2
BRPI0011172B8 (pt) derivados do 4,5-diaril-3(2h)-furanona como inibidores de ciclooxigenase-2
Lolli et al. A new class of ibuprofen derivatives with reduced gastrotoxicity
Küçükgüzel et al. Synthesis of tolmetin hydrazide–hydrazones and discovery of a potent apoptosis inducer in colon cancer cells
Chen et al. Syntheses and biological activities of sulfoximine-based acyclic triaryl olefins
Ramalho et al. The search for new COX-2 inhibitors: a review of 2002–2008 patents
Alam et al. Synthesis, anti-inflammatory, analgesic, COX1/2-inhibitory activity, and molecular docking studies of hybrid pyrazole analogues
Fowler et al. Inhibitory properties of ibuprofen and its amide analogues towards the hydrolysis and cyclooxygenation of the endocannabinoid anandamide
EP1391201A4 (en) MEDICAL COMPOSITIONS
Fomenko et al. Effects of conventional and hydrogen sulfide-releasing non-steroidal anti-inflammatory drugs in rats with stress-induced and epinephrine-induced gastric damage
Rasooli et al. Synergistic effects of deuterium depleted water and Mentha longifolia L. essential oils on sepsis-induced liver injuries through regulation of cyclooxygenase-2
Osmaniye et al. Design, synthesis and biological evaluation of new N‐acyl hydrazones with a methyl sulfonyl moiety as selective COX‐2 inhibitors
Huguenin et al. Evaluation of the antitumoral potential of different nitric oxide-donating non-steroidal anti-inflammatory drugs (NO-NSAIDs) on human urological tumor cell lines
Biava Introduction to COX inhibitors
PT1296665E (pt) Composições analgésicas e anti-inflamatórias contendo celecoxib e ibuprofeno
TR200000478T2 (tr) Prostaglandin endoperoksit H sentaz biyosentezi inhibitörleri olarak arilpiridazinonlar.
Dammann Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity
Rai et al. Synthesis of Some Novel 2‐[2‐(aroyl‐aroxy)‐methyl]‐4‐phenyl‐1, 3‐thiazoles as Potent Anti‐Inflammatory Agents
Aragade et al. Synthesis and biological evaluation of a novel series of pyrazolylcoumarins as anti-inflammatory and antioxidant agents
Berg et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, HN-56249: a novel compound exhibiting a marked preference for the human enzyme in intact cells
Gülcan et al. Marginally designed new profen analogues have the potential to inhibit cyclooxygenase enzymes

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIDO O PEDIDO COM BASE NOS ARTIGOS 8O E 11 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI.C07D 237/14, C07D 237/18, C07D 401/04, C07D 401/06, C07D 405/04, C07D 409/04, A61K 31/50, A61K 31/501, A61P 19/02, A61P 29/00

Ipc: C07D 237/14 (2011.01), A61K 31/50 (2011.01), C07D

B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 12A, 13A E 14A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2256 DE 01/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ATE A 21A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.